Background The current literature supports the immediate use of combinations of antihypertensive drugs in terms of ease of use and adherence, but the key issue whether combination therapy is more effective than monotherapy in the prevention of cardiovascular complications remains unproven.
Introduction
Hypertension remains the leading cause of cardiovascular morbidity and mortality worldwide [1] . Unfortunately, the rule of halves still applies even in affluent European countries [2] . About one-third of the population is hypertensive. Of those who are hypertensive, only 50% are on antihypertensive medications. Of those on blood pressure (BP) lowering drugs, only 50% have their BP controlled [2] .
The guidelines published by the European Societies of Hypertension and Cardiology (ESH/ESC) [3] and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) [4] recommend the initiation of antihypertensive treatment with combination therapy as an alternative to titrating, rotating and sequentially combining BP-lowering drugs of different classes. According to the ESH/ ESC guideline [3] , combination therapy has several advantages. Using the combination of two drugs at a low dose might avoid side-effects [3] . Second, adherence decreases with the pill burden [5] . Moreover, combination therapy gets round the time-consuming search for an effective monotherapy, so that BP targets can be reached faster [3] . Although the current literature supports the aforementioned contentions, the key issue whether combination therapy is more effective than monotherapy in the prevention of the cardiovascular complications associated with hypertension remains unproven. We, therefore, did a retrospective analysis of the database of the Systolic Hypertension in Europe trial (Syst-Eur) [6] [7] [8] .
Methods

Study design
The protocol of the Syst-Eur trial has been described in detail elsewhere [6] [7] [8] . In summary, eligible patients had to be at least 60 years old. They had a sitting systolic BP between 160 and 219 mmHg, with diastolic BP below 95 mmHg and a standing systolic BP of at least 140 mmHg. The entry BP was the mean of six sphygmomanometric readings with the patients seated, that is, two readings at each of three run-in visits on single-blind placebo. The Ethics Committees of the University of Leuven and the participating centres approved the protocol of the Syst-Eur trial. The Helsinki declaration for investigation in human participants served as the standard for the implementation of the trial. All participants in the 198 centres gave informed consent.
After stratification by centre, sex and previous cardiovascular complications, patients were randomized to doubleblind treatment with either active medication (n ¼ 2398) or matching placebo (n ¼ 2297). The study medications were stepwise titrated and combined to reduce sitting systolic BP by 20 mmHg or more to less than 150 mmHg. Active treatment was initiated with nitrendipine (firstline medication, 10-40 mg per day). If necessary to reach the systolic target BP, the calcium channel blocker was combined with or replaced by enalapril (second-line medication, 5-20 mg per day), hydrochlorothiazide (third-line medication, 12.5-25 mg per day) or both. In the control group, placebos matching the first-line, second-line and third-line active drugs were used similarly. All active medications and matching placebos were administered as single tablets.
When the double-blind trial was stopped on 14 February 1997 [7] , after a median follow-up of 2.0 years, the patients of the control group were switched to active antihypertensive therapy with the same study medications as used before in the active-treatment group, whereas the patients initially allocated active treatment continued active treatment [9] . In treatment-resistant patients, the open-label study medication could be associated with, or replaced by, any other antihypertensive drug. The extended follow-up ended on 31 December 2001 [9] .
During the double-blind trial [6, 7] and during the first year of the open-label study [9] , clinic visits were scheduled every 3 months. From the second year of the openlabel follow-up onwards, reports were due every 6 months [9] . At each visit, BP was measured twice in the sitting position and the two BP readings were averaged for analysis. For patients who withdrew from the study or who could not be followed up as planned, investigators collected information on vital status and incidence of endpoints at annual intervals. The Endpoint Committee, whose members were unaware of the random treatment allocation, reviewed the outcomes defined in the study protocols.
New-onset diabetes mellitus was the use of antidiabetic drugs, a fasting blood glucose concentration of at least 7.0 mmol/l, a random blood glucose concentration of at least 11.1 mmol/l or diabetes documented in practice or hospital records [10] .
Statistical analysis
For database management and statistical analysis, we used SAS version 9.2 (SAS Institute, Cary, North Carolina, USA). Comparison of means, medians and proportions relied on the standard normal z-test, MannWhitney test and the x 2 -statistic, respectively. Statistical significance was a P value of 0.05 or less on two-sided tests. The BP-lowering effect of enalapril in patients uncontrolled on nitrendipine was calculated by subtracting the BP after adding the second-line medication to the first-line study drug from the BP most recently preceding the initiation of enalapril treatment. Net between-group BP differences were calculated by subtracting the mean change during active treatment from the corresponding mean change in the control group.
The impact of combination therapy with nitrendipine and enalapril on outcome was assessed using two different approaches. The first approach only included data collected during the double-blind trial. The outcomes in patients randomized to active treatment and treated with nitrendipine plus enalapril were compared with those on the placebo's equivalent of this combination [8] . The second approach considered information collected during both the double-blind [6, 7] and open-label [9] phases of the study. Patients on active treatment with nitrendipine and enalapril were compared with patients remaining on nitrendipine monotherapy for the duration of the study. In the patients initially randomized to active treatment, baseline was set at the date of randomization, whereas in patients initially randomized to placebo, baseline was defined as the date of entry into the open label followup study.
All outcome analyses were performed according to the intention-to-treat principle. For clinical signs, symptoms and complaints, a per-protocol approach was applied. Unadjusted and adjusted between-group comparisons of disease outcomes relied on the log-rank test and Cox regression analysis, respectively. In Cox regression, we adjusted for sex, age, baseline systolic BP, previous cardiovascular complications and the phase of the study (open-label vs. double-blind phase, if applicable).
Results
Baseline characteristics
Of the 2398 patients randomized to active treatment, 1327 remained on monotherapy with nitrendipine for the whole duration of the double-blind trial, 515 progressed to combination therapy with nitrendipine and enalapril, 405 received hydrochlorothiazide and the remaining 151 were either on monotherapy with enalapril or were treated with unknown drugs (Fig. 1) . The corresponding numbers in the 2297 patients initially randomized to placebo were 859, 559, 782 and 97, respectively. Figure 2 shows the proportion of patients progressing during the double-blind trial to combination therapy with enalapril.
Age at randomization averaged 70.2 AE 6.7 years (Table 1) . Patients progressing to the second-line medication, compared with those remaining on monotherapy with the first-line medication, were more frequently treated with antihypertensive drugs before randomization (48.6 vs.
43.0%; P ¼ 0.003), had higher body mass index (27. (Table 1) were similar in patients allocated active treatment vs. placebo as well as in patients progressing to combination therapy vs. those remaining on the first-line medication.
Effects of adding enalapril to nitrendipine in the doubleblind trial In the 515 patients, who during the double-blind trial progressed to nitrendipine plus enalapril, but not hydrochlorothiazide, the median time interval between randomization and the start of enalapril was 8.8 months [5th-95th percentile interval (PI) 3.2-33.5]. In the 559 patients, who took the matching placebos, the median interval was also 8.8 months (5th-95th PI 3.3-36.4; P ¼ 0.88 for between-group difference). In the activetreatment group, the daily doses were 36.0 AE 9.0 mg for nitrendipine and 11.6 AE 5.9 mg for enalapril; in the placebo group, the number of tablets taken corresponded to 37.8 AE 6.8 mg and 13.0 AE 6.1 mg, respectively.
Outcome on combination therapy in Syst-Eur Thijs et al. 867 Flow of patients according to initial randomisation and intake of study medications in the double-blind trial [6, 7] and in the subsequent open follow-up study [9] .
The additional BP-lowering effect of enalapril in patients uncontrolled on nitrendipine was studied in the 515 actively treated patients and the 559 placebo patients who progressed to combination therapy with the first-line and second-line study medications. From the start of enalapril treatment until the last visit of the doubleblind trial, systolic BP decreased from 167.6 AE 14.7 to 164.8 AE 16.8 mmHg in the placebo group (P < 0.001) and from 164.2 AE 13.2 to 152.0 AE 13.5 mmHg in the activetreatment group (P < 0.001). Diastolic BP changed from 85.0 AE 7.9 to 84.2 AE 8.2 mmHg (P ¼ 0.016) and from 82.5 AE 7.7 to 78.8 AE 8.3 mmHg (P < 0.001), respectively. Thus, at the end of the double-blind trial (Fig. 3) , the net effect of adding enalapril averaged 9.5 mmHg systolic [95% confidence interval (CI) 7.5-11.4; P < 0.001] and 3.0 mmHg diastolic (95% CI 2.0-3.9; P < 0.001).
In the 515 actively treated patients and the 559 placebo patients who progressed to and remained on the combination therapy with the first-line and second-line medications, the net BP decreases from randomization to median follow-up (2.0 years), averaged 13.9 mmHg systolic (95% CI 12.0-15.7) and 4.8 mmHg diastolic (95% CI 3.9-5.7). The composite of all cardiovascular endpoints occurred at a rate, which was 42% lower (95% CI 7-64; P ¼ 0.02) in patients on active nitrendipine plus enalapril than in those on the matching combination of placebos. For stroke (À48%; P ¼ 0.072) and heart failure (À59%; P ¼ 0.057), the trends were similar, but did not reach statistical significance (Table 2) . A two-sided log-rank test with an overall sample size of 1074 participants (559 in the placebo group and 515 in the active-treatment group) provides 27% power at a 0.05 significance level to detect a hazard ratio of 0.70 when the event rate in the placebo group is 38.1 events per 1000 patient-years and median follow-up time is 1.8 years.
With cumulative adjustments applied for sex, age, history of cardiovascular complications, baseline systolic BP and previous antihypertensive treatment, the relative hazard ratio was statistically significant for all cardiovascular events (hazard ratio 0.49; 95% CI 0.30-0.79; P ¼ 0.0035) and for fatal combined with nonfatal heart failure (hazard ratio 0.34; 95% CI 0.13-0.91; P ¼ 0.032), with similar trends for fatal plus nonfatal stroke (hazard ratio 0.49; 95% CI 0.23-1.05; P ¼ 0.066) and fatal plus nonfatal cardiac events (hazard ratio 0.56; 95% CI 0.30-1.06; P ¼ 0.075).
Outcome on combination vs. monotherapy in the double-blind and open study At the end of the double-blind trial, 1691 patients originally randomized to placebo and 1826 patients allocated active treatment entered the open-label follow-up study. Thus, a total of 4089 patients received active study medication, either since randomization (active-treatment group, n ¼ 2398) or since the start of the open-label study (n ¼ 1691). Of these (Fig. 1) , 1552 remained on monotherapy with open-label nitrendipine until the end of the open follow-up study, 871 progressed to combination therapy with nitrendipine and enalapril, 1180 progressed to hydrochlorothiazide and the remaining 486 were either on monotherapy with enalapril or were treated with unknown drugs or were left untreated. Compared with patients remaining on monotherapy with nitrendipine (daily dose 24.9 AE 12.1 mg), participants treated with the combination of nitrendipine (35.6 AE 10.4 mg) plus enalapril (12.4 AE 7.4 mg), but not hydrochlorothiazide, included more men (37.5 vs. 32.0%; P ¼ 0.0097), were younger (69.6 AE 6.0 vs. 71.3 AE 7.1 years, P ¼ 0.0054), had higher baseline systolic BP (170.6 AE 12.8 vs. 165.5 AE 13.5 mmHg; P < 0.0001) and diastolic BP (84.9 AE 6.4 vs. 84.4 AE 6.4 mmHg; P ¼ 0.067) and higher body mass index (27.3 AE 4.3 vs. 26.5 AE 3.9 kg/m 2 ; P < 0.0001). However, both groups included a similar proportion of patients originally randomized to active treatment and placebo (60.2 vs. 62.1%; P ¼ 0.34). At 2 years after the initiation of active treatment (randomization in the active-treatment group and start of open follow-up in the placebo group), Proportion of patients in the active-treatment group (solid line) and in the placebo group (dotted line), who during the double-blind trial [7, 8] progressed to the combination of the first-line plus the second-line study medication. The curves are Kaplan-Meier estimates, in which the denominator is the number of patients available for analysis at each time point. C plac , N plac , C act and N act refer to the number of patients progressing to combination therapy with nitrendipine and enalapril and the total number of patients followed up at each time point in the placebo and active-treatment groups, respectively. The P value refers to the difference between the two treatment groups. the net BP reduction in patients on combined therapy compared with those remaining on monotherapy averaged 3.1 mmHg systolic (95% CI 1.8-4.5; P < 0.0001) and À0.1 mmHg diastolic (95% CI À0.8 to 0.6; P ¼ 0.74).
Combination therapy, compared with nitrendipine given as the only active study medication (Table 3 and Fig. 4) , significantly decreased total mortality (À46%; P ¼ 0.0002), cardiovascular mortality (À35%; P ¼ 0.039), the composite of all fatal and nonfatal cardiovascular endpoints (À28%; P ¼ 0.020) and fatal and nonfatal stroke (À46%; P ¼ 0.020). A two-sided log-rank test with an overall sample size of 2423 participants (1552 on monotherapy and 871 on combination therapy) achieves 71% power at a 0.05 significance level to detect a hazard ratio of 0.70 when the event rate in the monotherapy group is 24 events/1000 patient-years and median followup time is 4.8 years.
After cumulative adjustments for sex, age, history of cardiovascular complications, baseline systolic BP and initial randomization group (Fig. 5) , the hazard ratio remained statistically significant for all-cause mortality (hazard ratio 0.68; 95% CI 0.48-0.95; P ¼ 0.023), with similar trends for fatal combined with nonfatal stroke (hazard ratio 0.58; 95% CI 0.33-1.01; P ¼ 0.054) and all cardiovascular events (hazard ratio 0.77; 95% CI 0.58-1.03; P ¼ 0.081). The adjusted hazard ratios for cardiovascular mortality (hazard ratio 0.76; 95% CI 0.49-1.17; P ¼ 0.21), cardiac events (hazard ratio 0.80; 95% CI 0.56-1.17; P ¼ 0.21), myocardial infarction (hazard ratio 0.75; 95% CI 0.42-1.36; P ¼ 0.34) and heart failure (hazard ratio 0.91; 95% CI 0.52-1.58; P ¼ 0.73) did not approach significance. In a sensitivity analysis, which disregarded all events that had occurred during the first 9 months after baseline (approximately the median interval from randomization to progression to combination therapy in the double-blind trial), only total mortality (hazard ratio Table 1 Baseline characteristics in patients remaining on monotherapy with first-line study medication vs. patients progressing to the combination of the first-line with the second-line study medications The P value refers to the comparison of all patients remaining on monotherapy vs. those progressing to combination therapy. Significance of the difference between patients allocated placebo or active treatment within the group of patients remaining on monotherapy or progressing to combination therapy. M P < 0.05.
Fig. 3
Systolic and diastolic blood pressures at randomization and during double-blind follow-up in patients taking active nitrendipine plus enalapril (closed symbols) or taking the matching placebos (open symbols). The plotted points are mean AE SE. Numbers refer to the patients contributing to the plotted points.
0.68; 95% CI 0.48-0.97; P ¼ 0.033) was significantly lower on combination therapy than on monotherapy.
Signs, symptoms and complaints Table 4 lists the signs, symptoms and complaints that occurred during the double-blind phase of the trial on placebo and active combination therapy. Hypotensive symptoms, cough, flushing and ankle oedema occurred more frequently on active combination therapy, consisting of nitrendipine plus enalapril, than on the matching placebos. Combining data from the double-blind trial and open follow-up (Table 4) , hypotensive symptoms (5.4 vs. 2.7%), cough (7.5 vs. 4.1%) and ankle oedema (10.0 vs. 7.5%) occurred more frequently on the combination of active nitrendipine plus enalapril than on monotherapy with active nitrendipine, with similar trends for palpitations and new-onset atrial fibrillation.
Discussion
The key finding of this retrospective analysis of the double-blind and open phases of the Syst-Eur trial was that combination therapy consisting of nitrendipine plus enalapril, compared with the matching placebo's and monotherapy with active nitrendipine, was more effective in lowering BP and in the prevention of cardiovascular complications.
The majority of hypertensive patients require two or more agents to have their BP controlled [3, 4] . For example, in the Anglo-Scandinavian Cardiac Outcomes Trial, approximately 90% of patients required two or more antihypertensive drugs in an attempt to lower BP to levels lower than 140 mmHg systolic and 90 mmHg diastolic [11] . In the Hypertension Optimal Treatment study, patients needed on average 3.3 drugs to attain goal pressure [12] . In high-risk patients with diabetes, renal dysfunction or previous cardiovascular complications, the number of drugs needed was even higher [12] . In line with these findings, we currently noticed that risk factors clustered in patients who progressed to combination therapy. They were more frequently treated with antihypertensive drugs before randomization and had higher Active and placebo refer to the combination of active nitrendipine and active enalapril and to the combination of the matching placebos, respectively. The analysis was limited to the double-blind phase of the trial. a Percentage reduction on active treatment vs. placebo. b Number of endpoints prevented per 1000 patients actively treated for 2 years.
c Based on the log-rank test. The analysis includes both the double-blind and open follow-up phases of the study. Single refers to the patients on monotherapy with active nitrendipine and combination to patients on active nitrendipine plus active enalapril. a Percentage reduction on combination therapy vs. monotherapy. b Number of endpoints prevented per 1000 patients treated by combination therapy for 2 years.
c Based on the log-rank test.
Outcome on combination therapy in Syst-Eur Thijs et al. 871 Incidence of all-cause mortality (a), cardiovascular mortality (b), all cardiovascular events (c), and fatal and nonfatal stroke (d) during the double-blind trial [6, 7] plus open follow-up [9] in patients taking active nitrendipine in monotherapy (dotted line) or taking the combination of active nitrendipine plus enalapril (full line). Nm, Em, Nc, and Ec refer to the number of patients and the number of events at each time point in patients remaining on active monotherapy or progressing to active combination therapy, respectively. P values derived by the log-rank test refer to the significance of the difference between monotherapy and combination therapy. Unadjusted hazard ratios with 95% confidence interval are also given.
body mass index and more elevated systolic BP at randomization. New-onset atrial fibrillation tended to occur more frequently on combination therapy than on monotherapy, probably because patients progressing to the combination of active nitrendipine plus enalapril had more severe hypertension and because high BP is a major risk factor for atrial fibrillation [13] .
In a retrospective cohort study, Chapman et al. [5] studied adherence to concurrent antihypertensive and lipid-lowering therapy over a 90-day period. With adjustments applied for sex, age and other confounders, patients were more likely to be adherent if they had a history of cardiovascular disease or took fewer medications [5] . Along similar lines, other reports [14, 15] highlighted a strong inverse association between adherence to cardiovascular medications and the number of medications administered. Several studies suggested that simplifying a drug regimen by eliminating just one pill, by using a fixed-dose combination of two antihypertensive [16] or antidiabetic [17] agents instead of the combination of two pills, could improve adherence.
In a meta-analysis of 42 trials (10 968 patients), Wald et al. [18] quantified the incremental BP-lowering effect to be expected from a combination of any of two Incidence of all-cause mortality (a), cardiovascular mortality (b), all cardiovascular events (c), and fatal and nonfatal stroke (d) during the double-blind trial [6, 7] plus open follow-up [9] in patients taking active nitrendipine in monotherapy (dotted line) or taking the combination of active nitrendipine plus enalapril (full line). The number of events and patients at risk are the same as in Fig. 4 . The survival function estimates and the hazard ratios (95% confidence interval) were adjusted for sex, age, history of cardiovascular complications, baseline systolic blood pressure, and initial randomization group. P values derived by Cox regression refer to the significance of the difference between monotherapy and combination therapy.
classes of antihypertensive agents [thiazides, b-blockers, angiotensin-converting enzyme (ACE) inhibitors or calcium-channel blockers] over those of administrating a single drug. These investigators noticed that the BPlowering effects of combining antihypertensive drugs of different drug classes were close to being exactly additive [18] . Furthermore, comparison of the results of the metaanalysis by Wald et al. [18] with those of another metaanalysis of different doses of the same drug [19] clarified that doubling the dose of one drug has approximately one-fifth of the incremental effect in lowering BP (estimate 0.22; 95% CI 0.19-0.25) [18] compared with combining two drugs of different classes. Law's meta-analysis [19] , moreover, showed that the prevalence of symptoms with two drugs in combination was less than additive. This was also the case in our current study, with the exception of hypotensive symptoms, cough and ankle oedema, which occurred more frequently on combination therapy with nitrendipine plus enalapril than on monotherapy with nitrendipine. The purely arteriolar dilatation and consequent increase in capillary pressure explains the ankle oedema caused by dihydropyridines [20, 21] . Renin system inhibitors, such as ACE inhibitors [22, 23] or angiotensin receptor blockers [24] , induce venular dilatation and adding a renin system inhibitor to a calcium-channel blocker, therefore, reduces the pitting oedema [22] [23] [24] . We did not observe such effect in our current study, probably because the mean daily dose of nitrendipine in patients progressing to combination therapy was about 40% higher than in those staying on monotherapy.
As reviewed elsewhere [22] , several mechanisms can explain why the combination of a dihydropyridine calcium-channel blocker and an ACE inhibitor is clinically useful. First, dihydropyridines cause a variable amount of reflex sympathetic activation, whereas ACE inhibitors blunt sympathetic activity. Second, dihydropyridines produce an almost exclusive arteriolar vasodilatation, whereas association of an ACE inhibitor produces a more balanced arteriolar and venular vasodilatation. Finally, ACE inhibitors antagonise the reactive increase of renin release and the consequent generation of angiotensin II in response to the vasodilatory and natriuretic effects associated with the intake of dihydropyridines.
The present study must be interpreted within the context of its potential limitations and strengths. First, the current retrospective analyses were not predefined and the analyses combining data from the double-blind trial and the open follow-up did not follow the lines of the initial randomization. On the contrary, to make best use of the existing trial data, certainly for clinical issues unlikely to be addressed in future trials, retrospective [8, 25, 26] or posthoc [27, 28] analyses with all required caveats, are common practice. Such publications might reflect publication bias, because secondary analyses with null results are unlikely to be published. Second, we only studied older patients with isolated systolic hypertension. Our findings might, therefore, not be generalizable to younger participants or to patients with diastolic or systolic BP combined with diastolic hypertension. Third, a fixed combination of nitrendipine 20 mg plus enalapril 10 mg, which is commercially available and was given once daily, proved during 3 months of follow-up to be effective in bringing BP to goal in hypertensive patients with previously uncontrolled hypertension [29] . In this Spanish observational multicentre study in primary care [29] , the daily dose of enalapril was similar as in our current study but that of nitrendipine was approximately 45% lower. Finally, the Syst-Eur trial did not include a detailed assessment of adherence to therapy.
In conclusion, in keeping with the stronger BP reduction, combination therapy with nitrendipine plus enalapril may improve outcome in older patients with isolated systolic hypertension over and beyond the benefits seen with nitrendipine monotherapy. Fixed-dose combinations for the treatment of hypertension have been in use since 1961 [30] . Expert committees [3, 4] will now have to evaluate
Outcome on combination therapy in Syst-Eur Thijs et al. 873 Values are number of patients (percentage). New-onset diabetes mellitus was the use of antidiabetic drugs, a fasting blood glucose concentration of at least 7.0 mmol/l, a random blood glucose concentration of at least 11.1 mmol/l, or diabetes documented in practice or hospital records [10] .
whether our outcome results from a posthoc analysis can lend further support to the initiation of treatment with fixed-dose combination tablets above the more laborious strategy, still preferred by many hypertension specialists [30] , of starting with one drug and subsequently optimizing therapy in terms of BP lowering and tolerance by substitution or addition of other compounds. Only randomized clinical trials of sufficient duration comparing both strategies in terms of target organ damage or incidence of cardiovascular complications can provide a definite answer to the question at hand.
